Thursday, July 18, 2019 10:36:35 AM
https://www.nejm.org/media-center/publication-process
Publication Process
The New England Journal of Medicine (NEJM) employs a rigorous peer review and editing process to evaluate all manuscripts for scientific accuracy, novelty, and importance. This painstaking publication process has been tested over many decades and is a major reason for the Journal’s reputation as the world’s leading medical journal.
NEJM receives over 4,500 original research submissions each year — more than a dozen each business day — with over half coming from outside the U.S.
At least five experts review and edit each Original Article or Special Article manuscript published by NEJM. Of thousands of research reports submitted each year, about 5% are eventually published by NEJM.
The peer review process works to improve research reports while preventing overstated results from reaching physicians and the public. Each published NEJM manuscript benefits from hundreds of hours of work by editors, statistical experts, manuscript editors, illustrators, proofreaders, and production personnel, who work to ensure that every paper meets exacting standards.
About the Editors
The NEJM core editorial team comprises nine physician editors and one Ph.D. geneticist.
The Path of a Research Manuscript
NEJM Executive Deputy Editor Mary Beth Hamel, M.D., M.P.H., reviews each research manuscript submission and determines whether it meets essential NEJM criteria to warrant further consideration and peer review. About 10% of submitted papers are declined at this stage without further editorial consideration.
A paper passing Dr. Hamel’s initial review moves to an appropriate associate editor, who determines whether it meets fundamental criteria for:
Quality
Novelty
Potential clinical impact
If so, the associate editor sends the manuscript to at least two peer reviewers.
Should an associate editor wish to decline a paper without peer review, it goes first to a deputy editor for a second opinion; if the deputy editor disagrees with the associate editor, the paper will be sent on for peer review.
Peer Review
NEJM maintains a database of more than 30,000 peer reviewers worldwide in all areas of medicine. In almost all cases, two peer reviewers evaluate each submission within one to two weeks and submit written reports to the NEJM editors.
During peer review, all manuscripts are considered privileged communications. Without prior approval from the NEJM editorial office, peer reviewers are expressly prohibited from:
Copying manuscripts
Sharing with others
Discussing their personal evaluations or recommendations
NEJM also instructs peer reviewers to:
Report immediately any possible personal, professional, or financial conflicts of interest with authors or related to a paper’s topic; where conflicts arise, NEJM editors find substitute reviewers.
Destroy manuscript copies once reviews are complete.
Full Editorial Team Review and Statistical Review
Using peer reviews and their own judgments, NEJM associate editors then decide whether to decline a manuscript (a decision which must be seconded by a deputy editor) or to bring it to a weekly editorial meeting attended by all NEJM deputy editors, associate editors, and statistical consultants for discussion and debate.
Following discussion at a weekly editorial meeting, a paper will be assigned one of three statuses:
Rejection: Publication is declined; reviewers’ comments are provided to authors.
Provisional Rejection: The manuscript is not suitable for publication unless the authors conduct further research or collect additional data.
Revision: NEJM has interest in the paper, but the manuscript is not acceptable in its current form and must be revised before further consideration for publication. If a manuscript is moved to Revision status, the paper will be sent on for statistical review — an additional, rigorous review step. Most research manuscripts published by NEJM undergo at least one statistical review by one of five statistical consultants prior to acceptance.
More on the Revision Process
The associate editor communicates a paper’s status to its authors in a letter detailing questions raised in the review process and, where applicable, recommending revisions needed to meet NEJM standards for publication. Authors respond to the associate editor with a revised manuscript and letter detailing their changes.
When authors resubmit a revised manuscript, the associate editor again reviews it and decides whether further peer or statistical review is needed and often brings the paper back to a weekly editorial meeting for further discussion.
If additional outside review is not needed, the manuscript will be sent to a deputy editor for additional editing and revisions in collaboration with the associate editor and its authors.
Final Review & Acceptance for Publication
The NEJM Editor-in-Chief reviews all final (revised) submissions and may raise further questions. The Editor-in-Chief is the only person who can officially accept a paper for publication. Following Dr. Drazen’s formal acceptance for publication, a paper will then move through rigorous processes for manuscript editing, production, illustration, design, and publication.
Recent AVXL News
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM